Company Description
FOXO Technologies Inc. develops epigenetic biomarkers technology solutions in the United States.
The company applies automated machine learning and artificial intelligence (AI) technologies to discover epigenetic biomarkers of human health, wellness, and aging.
It offers FOXO Labs, a commercializing proprietary epigenetic biomarker technology enables the adoption of saliva-based health and wellness biomarker solutions for underwriting and risk assessment; and Bioinformatics services that provides data solutions using AI and machine learning for data analysis and processing, and quality checking for academia, healthcare, government, and pharmaceutical research customers.
FOXO Technologies Inc. was founded in 2020 and is based in Minneapolis, Minnesota.
| Country | United States |
| Founded | 2019 |
| Industry | Health Information Services |
| Sector | Healthcare |
| Employees | 29 |
| CEO | Seamus Lagan |
Contact Details
Address: 729 North Washington Avenue, Suite 600 Minneapolis, Minnesota 55401 United States | |
| Phone | 612 562 9447 |
| Website | foxotechnologies.com |
Stock Details
| Ticker Symbol | FOXO |
| Exchange | NYSEAMERICAN |
| Stock Type | Common Stock |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001812360 |
| CUSIP Number | 351471305 |
| ISIN Number | US3514713052 |
| Employer ID | 85-1050265 |
| SIC Code | 8731 |
Key Executives
| Name | Position |
|---|---|
| Seamus Lagan | Chief Executive Officer and Director |
| Martin Christopher Ward FCA | Interim Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 24, 2025 | D | Notice of Exempt Offering of Securities |
| Mar 21, 2025 | D/A | Filing |
| Mar 19, 2025 | 8-K | Current Report |
| Mar 18, 2025 | 8-K | Current Report |
| Mar 12, 2025 | 8-K | Current Report |
| Mar 7, 2025 | D | Notice of Exempt Offering of Securities |
| Mar 5, 2025 | 8-K | Current Report |
| Mar 3, 2025 | D | Notice of Exempt Offering of Securities |
| Feb 28, 2025 | PRE 14C | Filing |
| Feb 24, 2025 | 8-K | Current Report |